Literature DB >> 18712680

TNF-alpha/IL-1/NF-kappaB transduction pathway in human cancer prostate.

M Royuela1, G Rodríguez-Berriguete, B Fraile, R Paniagua.   

Abstract

TNFalpha exerts apoptosis throughout an intracellular transduction pathway that involves the kinase proteins TRAF-2 (integration point of apoptotic and survival signals), ASK1 (pro-apoptotic protein), MEK-4 (p38 activator and metastasis suppressor gene), JNK (stress mitogen activated protein kinase) and the transcription factor AP-1. TNFalpha also exerts proliferation by p38 activation, or when TRAF-2 simultaneously induces the transcription factor NF-kappaB by NIK. NIK and p38 may also be activated by IL-1. P38 activated several transcription factors such as Elk-1, ATF-2 and NF-kappaB. NIK also may activate NF-kappaB. The aim of the present article was to evaluate the different components of this TNFalpha/IL-1 transduction pathway in human prostate carcinoma (PC) in comparison with normal human prostate. In prostate cancer, pro-apoptotic TNFalpha/AP-1 pathway is probably inactivated by different factors such as p21 (at ASK-1 level) and bcl-2 (at JNK level), or diverted towards p38 or NIK activation. IL-1alpha enhances proliferation through IL-1RI that activates either NIK or p38 transduction pathway. P38 and NIK activate different transcription factors related with cell proliferation and survival such as ATF-2, Elk-1 or NF-kappaB. In order to search a possible target to cancer prostate treatment we proposed that inhibition of several proinflamatory cytokines such as IL-1 and TNFalpha might be a possible target for PC treatment, because decrease the activity of all transduction pathway members that activate transcription factors as NF-kappaB, Elk-1 or ATF-2.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18712680     DOI: 10.14670/HH-23.1279

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  21 in total

1.  Nna1 mediates Purkinje cell dendritic development via lysyl oxidase propeptide and NF-κB signaling.

Authors:  Jianxue Li; Xuesong Gu; Yinghua Ma; Monica L Calicchio; Dong Kong; Yang D Teng; Lili Yu; Andrew M Crain; Timothy K Vartanian; Renata Pasqualini; Wadih Arap; Towia A Libermann; Evan Y Snyder; Richard L Sidman
Journal:  Neuron       Date:  2010-10-06       Impact factor: 17.173

Review 2.  The oncolytic virus ΔPK has multimodal anti-tumor activity.

Authors:  Laure Aurelian; Dominique Bollino; Aric Colunga
Journal:  Pathog Dis       Date:  2016-05-29       Impact factor: 3.166

3.  Role of microRNA-141 in colorectal cancer with lymph node metastasis.

Authors:  Li Feng; Hongqing Ma; Liang Chang; Xinliang Zhou; Na Wang; Lianmei Zhao; Jing Zuo; Yudong Wang; Jing Han; Guiying Wang
Journal:  Exp Ther Med       Date:  2016-09-27       Impact factor: 2.447

4.  A mimic of phosphorylated prolactin induces apoptosis by activating AP-1 and upregulating p21/waf1 in human prostate cancer PC3 cells.

Authors:  Lianlian DU; Wei Wu
Journal:  Oncol Lett       Date:  2012-08-23       Impact factor: 2.967

5.  Apoptosis inhibition can be threatening in Aβ-induced neuroinflammation, through promoting cell proliferation.

Authors:  A Abdi; H Sadraie; L Dargahi; L Khalaj; A Ahmadiani
Journal:  Neurochem Res       Date:  2010-09-17       Impact factor: 3.996

6.  The role of Rac1 in the regulation of NF-κB activity, cell proliferation, and cell migration in non-small cell lung carcinoma.

Authors:  Adam Gastonguay; Tracy Berg; Andrew D Hauser; Nathan Schuld; Ellen Lorimer; Carol L Williams
Journal:  Cancer Biol Ther       Date:  2012-06-01       Impact factor: 4.742

7.  Effects of cyclohexanone analogues of curcumin on growth, apoptosis and NF-κB activity in PC-3 human prostate cancer cells.

Authors:  Xingchuan Wei; Zhi-Yun DU; Xiao-Xing Cui; Michael Verano; Rong Qing Mo; Zhi Kai Tang; Allan H Conney; Xi Zheng; Kun Zhang
Journal:  Oncol Lett       Date:  2012-05-10       Impact factor: 2.967

8.  Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression.

Authors:  Diping Wang; R Bruce Montgomery; Lucy J Schmidt; Elahe A Mostaghel; Haojie Huang; Peter S Nelson; Donald J Tindall
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

Review 9.  Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.

Authors:  Tristan M Sissung; Silja Thordardottir; Erin R Gardner; William D Figg
Journal:  Anticancer Agents Med Chem       Date:  2009-12       Impact factor: 2.505

10.  Role of IAPs in prostate cancer progression: immunohistochemical study in normal and pathological (benign hyperplastic, prostatic intraepithelial neoplasia and cancer) human prostate.

Authors:  Gonzalo Rodríguez-Berriguete; Benito Fraile; Fermín R de Bethencourt; Angela Prieto-Folgado; Nahikari Bartolome; Claudia Nuñez; Bruna Prati; Pilar Martínez-Onsurbe; Gabriel Olmedilla; Ricardo Paniagua; Mar Royuela
Journal:  BMC Cancer       Date:  2010-01-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.